Moderna investors prepare for a phase 3 reveal
Intismeran autogene’s Interpath-001 trial reads out this year.
One Genmab Rybrevant challenge is rendered moot
GEN1286 looks dead, though MCLA-129 continues for now.
Epkinly fails its first confirmatory test
And that could affect the drug's third-line accelerated approval.
J&J claims another second-line Tecvayli win
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
ImmunityBio gets lung cancer boost
But PFS data are lacking, and there are questions about first and second-line plans.
